Research-based biopharmaceutical company operating as MSD outside the United States and Canada.
merck.comLegal name
Merck & Co., Inc.
Known outside US and Canada as
MSD
Headquarters
Rahway, New Jersey, United States
Business areas
Pharmaceuticals, vaccines, and animal health
Employees
About 75,000 (December 31, 2025)
Revenue (FY2025)
US$65.0 billion
R&D expense (FY2025)
US$15.8 billion
CEO
Robert M. Davis
Listed on
NYSE: MRKWebsite
merck.comMerck & Co., Inc. is a research-based biopharmaceutical company headquartered in Rahway, New Jersey. The company is known as MSD outside the United States and Canada and is listed on the New York Stock Exchange under the ticker MRK.
Its businesses span prescription medicines, vaccines, biologic therapies, and animal health products. The company sells products through its pharmaceutical and animal health segments.
Merck reported revenue of US$65.0 billion and research and development expense of US$15.8 billion for 2025. It employed about 75,000 people at December 31, 2025.
Chairman and Chief Executive Officer
Executive Vice President and Chief Financial Officer
Executive Vice President and President, Merck Research Laboratories
President, MSD International Human Health
Interview experience
3.7 out of 5
Interview difficulty
Mostly moderate
Interview process length
Reported across five source buckets
Browse question banks by role, round and company, with answers and examples.
2 to 15 years
₹8.0 lakh to ₹8.8 lakh per year
104 Salaries submitted
10 to 20 years
₹10.2 lakh to ₹11.3 lakh per year
76 Salaries submitted
4 to 5 years
₹24.7 lakh to ₹28.5 lakh per year
57 Salaries submitted
7 to 8 years
₹23.9 lakh to ₹27.7 lakh per year
57 Salaries submitted
4 to 9 years
₹23.2 lakh to ₹27.7 lakh per year
38 Salaries submitted
1 to 5 years
₹13.4 lakh to ₹17.3 lakh per year
33 Salaries submitted
Compare reported pay ranges and find roles that fit your experience.
Pune, Maharashtra, India • Full-Time
Hyderabad, Telangana, India • Full-Time
Hyderabad, Telangana, India • Full-Time
Hyderabad, Telangana, India • Full-Time
Pune, Maharashtra, India • Full-Time
Hyderabad, Telangana, India • Full-Time
Free guides to AI video screens, coding tests and how scoring works.
July 21, 2026
Once-weekly oral HIV regimen maintained virological suppression in study
Merck and Gilead reported study results for an investigational once-weekly oral regimen of islatravir and lenacapavir in adults who switched treatment.
#Research #HIV
View postJuly 16, 2026
FDA approves once-daily oral PCSK9 inhibitor LIPFENDRA
Merck announced US FDA approval of LIPFENDRA to reduce LDL cholesterol in adults with hypercholesterolemia.
#FDA #Cardiovascular
View postJuly 15, 2026
Merck to present HIV pipeline data at AIDS 2026
The company said it would present research on daily, weekly, and monthly HIV treatment and prevention options at AIDS 2026.
#HIV #ClinicalResearch
View postJuly 15, 2026
KEYTRUDA monotherapy improved progression-free survival in study
Merck reported that KEYTRUDA monotherapy met the progression-free survival endpoint in certain patients with advanced or recurrent endometrial cancer.
#Oncology #ClinicalTrial
View postJuly 10, 2026
FDA approves KEYTRUDA regimens with PADCEV for bladder cancer
Merck announced FDA approval of KEYTRUDA and KEYTRUDA QLEX with PADCEV for treatment before and after surgery in certain patients with muscle-invasive bladder cancer.
#Oncology #FDA
View postMerck develops and sells prescription medicines, vaccines, biologic therapies, and animal health products.
Last updated:
